Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V-01-351 + V-01D
- Development stage
- Phase 2
- Lead developer
- Livzon Pharmaceutical
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
V-01D-351 (also referred to as V-01-351 + V-01D) is a bivalent recombinant protein subunit COVID-19 vaccine developed by Livzon Pharmaceutical Group (Livzon Bio). The vaccine is designed as a heterologous booster for individuals who have previously received a primary series of inactivated COVID-19 vaccines. It incorporates antigens targeting the SARS-CoV-2 Beta (B.1.351) and Delta (B.1.617.2) variants. In clinical trials, V-01D-351 has demonstrated the ability to elicit strong neutralizing antibody responses against the prototype strain, Delta, and Omicron (BA.1) variants, showing significantly higher titers compared to monovalent boosters. The vaccine has reached Phase 2 clinical evaluation in China and has exhibited a favorable safety profile with predominantly mild adverse reactions.
- Other names
- V-01D-351 Bivalence VaccineV01D-351 Bivalence VaccineV 01D-351 Bivalence Vaccine
02
Targets
RBD (SARS-CoV-2 spike receptor-binding domain)
Beyond the preview
Go deeper on V-01-351 + V-01D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V-01-351 + V-01D.